Consilium MedicumConsilium Medicum2075-17532542-2170Consilium Medicum94269Research ArticleDiuretics in the treatment of arterial hypertension: the role of torasemideMorozovaT. Etemorozova@gmail.comYudinaI. Yu-I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation15052015175141828122021Copyright © 2015, Consilium Medicum2015Diuretics are widely used in clinical practice in the treatment of arterial hypertension. The thiazide (thiazide-type) and loop diuretics are widely used in general clinical practice. The article deals with the questions of rational choice of diuretics, using the available evidence-based data, the results of drug interaction and the monitoring of efficacy and safety of the therapy. The special attention is paid to torasemide - loop diuretic, which is recommended for long-term pharmacotherapy of arterial hypertension.arterial hypertensionpharmacotherapythe treatment of arterial hypertensionantihypertensive therapyantihypertensive drugsdiureticsthiazide diureticthiazide-type diureticshydrochlorothiazideindapamideloop diureticsdrug interactiontorasemideартериальная гипертензияфармакотерапиялечение артериальной гипертензииантигипертензивная терапияантигипертензивные препаратыдиуретикитиазидные диуретикитиазидоподобные диуретикигидрохлоротиазидиндапамидпетлевые диуретикилекарственные взаимодействияторасемид[2013 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31 (7): 1281-357.][Рекомендации по лечению артериальной гипертонии. ESH/ESC 2013. Рос. кардиол. журн. 2014; 1 (105): 7-94.][2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults. JAM 2014; 311 (5): 507-20. Doi:10.1001/Jama.2013.284427.][Леонова М.В., Штейнберг Л.Л., Белоусов Ю.Б. и др. Результаты фармакоэпидемиологического исследования артериальной гипертонии Пифагор IV: приверженность врачей. Рос. кардиол. журн. 2015; 1 (117): 59-66; http://dx.doi.org/10.15829/1560-4071-2015-1-59-66][Juaquerto D.C, Schini V.B, Vanhoutte .PM. Indapamide potentiates the endothelium - depend production of cyclic guanosine monophosphate by bradykinine in the canine femoral artery. Am Heart J 1991; 122 (2): 1204-9.][Gosse Ph, Sheridan D, Zannad F et al. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus enalapril 20 mg: the LIVE Study. J Hypertension 2000; 18: 1465-75.][Marre M, Garcia-Puig J, Kokot F et al. Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: the NESTOR study. J Hypertension 2004; 22: 1613-22.][The HYVET Study Group. Treatment of Hypertension in Patients 80 Years of Age or Older. N Engl J Med 2008; 358.][Weidmann P. Metabolic profile of indapamide sustained - release in patients with hypertension. Drug Safety 2001; 24: 1155-65.][Kostis J.B, Wilson A.C, Fruedenberger R.S. Long term effect of diuretic based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol 2005; 95: 29-35.][Marre M, Garcia-Puig J, Kokot F et al. Efficacy of indapamide SR compared with enalapril in elderly hypertensive patients with type 2 diabetes. Am J Hypertension 2007; 20: 90-7.][Weidmann P. Metabolic profile of indapamide sustained - release in patients with hypertension. Drugs Safety 2001; 24: 1155-65.][Hypertension Detection and Follow - up Program Cooperative Group. JAMA 1979; 242: 2562-71.][Multiple Risk Factor Intervention Trial Research Group. Circulation. 1990; 82: 1616-28.][SHEP Cooperative Research Group. JAMA 1991; 265: 3255-64.][ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. JAMA 2002; 288: 2981-97.][Carter B et al. Hypertension 2004; 43: 4-9.][Calhoun D et al. Circulation 2008; 117: e510-e526.][Bakris G et al. J Clin Hypertens (Greenwich) 2008; 10: 707-13.][NICE clinical guideline. Clinical management of primary hypertension in adults. 2011. http://www.nice.org.uk/guidance/cg127/chapter/1-guidance][Peters R, Beckett N, Forette F et al. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double - blind, placebo controlled trial. Lancet Neurol 2008; 7: 683-9.][The HYVET Study Group. Treatment of Hypertension in Patients 80 Years of Age or Older. N Engl J Med 2008; 358.][Морозова Т.Е. Артериальная гипертония у пожилых: особенности течения и выбор терапии. Consilium Medicum. 2012; 14 (5): 12-6.][ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur Heart J 2012; 33: 1787-847.][Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН (четвертый пересмотр). Сердечная недостаточность. 2013; 14; 7.][De la Sierra A, Segura J, Banegas J.R et al. Clinical Features of 8295 Patients With Resistant Hypertension Classified on the Basis of Ambulatory Blood Pressure Monitoring. Hypertension 2011; 57: 898-902.][Taler S.J, Textor S.C, Augustine J.E. Resistant hypertension: comparing hemodynamic management to specialist care. Hypertension 2002; 39: 982-8.][Brater D.C, Leinfelder J, Anderson S.A. Clinical pharmacology of torasemide, a new loop diuretic. Clin Pharmacol Ther 1987; 42: 187-92.][Masereel B, Ferrari P, Ferrandi M et al. Na+,2Cl-,K+ cotransport system as a marker of antihypertensive activity of new torasemide derivatives. Eur J Pharmacol 1992; 4; 219 (3): 385-94.][Spieker C, Zidek W, Hacker W et al. Assessment of intracellular sodium and calcium in essential hypertension during diuretic treatment. Arzneimittelforschung 1988; 38 (1A): 188-90.][Yamanaga K, Uchida T, Kido H et al. But not frusemide, increases intracellular cAMP and cGMP content in the aorta of the renal hypertensive rat. J Pharm Pharmacol 1992; 44 (1): 64-5.][Карпов Ю.А. Торасемид: рекомендации для клинического применения при хронической сердечной недостаточности и артериальной гипертензии. Рос. мед. журн. 2014; 23: 1676-80.][Жиров И.В. Место петлевых диуретиков в современных стандартах лечения ХСН. РМЖ. 2012; 25: 1298-304.][Cosin J, Diez J. TORIC investigators. Torasemide in chronic heart failure: Results of the TORIC study. Eur J Heart Fail 2002; 4: 507-13.][Muller K, Gamba G, Jaquet F, Hess B. Torasemide vs furosemide in primary care patients with chronic heart failure NYHA II to IV - Efficacy and quality of life. Eur J Heart Fail 2003; 5: 793-801.][Lopez B, Querejeta R, Gonzalez A et al. Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. J Am Coll Cardiol 2004; 2; 43 (11): 2028-35.][TORAFIC Investigators Group. Effects of prolonged - release torasemide versus furosemide on myocardial fibrosis in hypertensive patients with chronic heart failure: a randomized, blinded - end point, active - controlled study. Clin Ther 2011; 33 (9): 1204-13.][Жиров И.В., Горюнова Т.В., Осмоловская Ю.Ф., Терещенко С.Н. Торасемид пролонгированного высвобождения у пациентов с хронической сердечной недостаточностью. Эффективная фармакотерапия. Кардиология и ангиология. 2014; 3 (25): 18-24.][Achhammer I, Metz P. Low dose loop diuretics in essential hypertension. Experience with torasemide. Drugs 1991; 41 (Suppl. 3): 80-91.][Гиляревский С.Р., Орлов В.А., Кузьмина И.М., Голшмид М.В. Может ли торасемид пролонгированного действия стать альтернативой тиазидным диуретикам при артериальной гипертонии? Мнение эксперта. Рос. мед. журн. 2012; 20: 1038-43.][Ткачева О.Н., Рунихина Н.К., Шарашкина Н.В. Торасемид: дополнительные преимущества применения при артериальной гипертензии у женщин в постменопаузе. Системные гипертензии. 2013; 2: 9-13.][Achhammer I, Eberhard R. Comparison of serum potassium levels during long - term treatment of hypertension patients with 2,5 mg torasemide o.d. or 50 mg triamterene/25 mg hydrochlorothiazide o.d. Prog Pharmaco. Clin Pharmacol 1990; 8: 211-20.][Baumgart P. Torasemide in comparison with thiazides in the treatment of hypertension. Cardiovasc Drugs Ther 1993; 7 (Suppl. 1): 63-8.][Coca A. Long - term blood pressure control and metabolic disorders induced by torasemide in hypertension. Am J Hypertens 2001; 14: 116A.][Агеев Ф.Т., Жубрина Е.С., Середенина Е.М. и др. Сравнительная эффективность и безопасность длительного применения торасемида и фуросемида у больных с компенсированной сердечной недостаточностью. Влияние на маркеры фиброза миокарда. Сердечная недостаточность. 2013; 14 (2): 55-62.]